Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation.
Ruiz
Stéphanie
S
Papy
Emmanuelle
E
Da Silva
Daniel
D
Nataf
Patrick
P
Massias
Laurent
L
Wolff
Michel
M
Bouadma
Lila
L
D000328:Adult; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D000077336:Caspofungin; D054714:Echinocandins / Q000097:blood / Q000493:pharmacokinetics*; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects*; D005260:Female; D006801:Humans; D055666:Lipopeptides; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D009205:Myocarditis / Q000150:complications; D011743:Pyrimidines / Q000097:blood / Q000493:pharmacokinetics*; D012770:Shock, Cardiogenic / Q000209:etiology / Q000628:therapy; D014230:Triazoles / Q000097:blood / Q000493:pharmacokinetics*; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D065819:Voriconazole
Clin Pharmacokinet. 2003;42(5):403-17
12739981
Crit Care Med. 2008 May;36(5):1404-11
18434909
Clin Infect Dis. 2008 Jan 15;46(2):201-11
18171251
Intensive Care Med. 2007 Jun;33(6):1018-24
17404709
Antimicrob Agents Chemother. 2004 Mar;48(3):970-8
14982791